Biguanidylated chitosan nanofiber scaffold: A green approach to promote osteogenesis in calvarial bone regeneration.
Saber M., Shaabani A., Sedghi R., Motasadizadeh H., Salimiyan N., Gholami M.
Animal Study, published in Carbohydr Polym (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Carbohydr Polym (2025)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 40484585
- DOI
- 10.1016/j.carbpol.2025.123736
- Citations
- 2
Abstract (original English)
Developing advanced materials for calvarial bone defects is crucial due to the limitations of conventional scaffolds. Chitosan (CS) is biocompatible and promotes bone growth, but its poor water solubility and weak mechanical properties limit its effectiveness. This study introduces a green method to create water-soluble chitosan-based scaffolds to overcome these drawbacks while enhancing antibacterial activity. Biguanidylated chitosan (CSG) was synthesized and combined with polyvinyl alcohol (PVA) to fabricate a novel electrospun nanofiber scaffold (PCSG) using water as the solvent, with heat treatment improving its stability in aqueous environments without additional chemicals. Compared to conventional CS/PVA (PCS) scaffolds, PCSG showed superior properties. Notably, PCSG40 demonstrated a 2.07-fold increase in ultimate tensile strength, a 2.13-fold increase in elongation at break, and a 1.58-fold increase in compressive strength over PCS40. In vitro assays confirmed PCSG40's non-cytotoxicity towards human adipose-derived mesenchymal stem cells (hADSCs) and revealed up to 25 % higher expression of osteogenic differentiation markers compared to PCS40. In vivo implantation in rat calvarial defects demonstrated that the PCSG40 scaffold promoted over 35 % more bone regeneration than PCS40. Additionally, it exhibited significant antibacterial properties against Staphylococcus aureus
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.